Drug Profile

ATT 001 - Ariceum Therapeutics

Alternative Names: 123I labelled PARPi; AT-001 - Ariceum Therapeutics; ATT-001; I-123 labelled PARPi; Iodine-123 labelled PARP inhibitor; THG 009

Latest Information Update: 13 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Theragnostics
Developer Ariceum Therapeutics
Class Antineoplastics; Drug conjugates; Iodine radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Mar 2024 ATT 001 is still in preclinical trials for Solid tumours in United Kingdom
04 Mar 2024 Ariceum Therapeutics plans to initiate the phase I CITADEL-123 trial for Glioblastoma in United Kingdom in June 2024
29 Feb 2024 UK MHRA approves CTA application for ATT 001 in Glioblastoma to conduct phase I clinical trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com